Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03870490 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects
A Phase 1 study, sponsored by Venatorx Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03870490 is a Phase 1 study that has completed, run by Venatorx Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT03870490, a Phase 1 study, has completed, sponsored by Venatorx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single-center, open-label study to assess safety and pharmacokinetics of VNRX-5133 and cefepime in the epithelial lining fluid in healthy adult male and female subjects.
Interventions
- DRUG VNRX-5133 + cefepime
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-03-14 |
| Est. Completion | 2019-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03870490
The ClinicalTrials.gov registry entry for NCT03870490 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Venatorx Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VNRX-5133 + cefepime is the first listed.
NCT03870490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03870490 about?
NCT03870490 is a clinical study titled "Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects". This is a single-center, open-label study to assess safety and pharmacokinetics of VNRX-5133 and cefepime in the epithelial lining fluid in healthy adult male and female subjects.
What is the current status of trial NCT03870490?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2019-03-14. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03870490?
The interventions under investigation include: VNRX-5133 + cefepime (DRUG).
Who is sponsoring clinical trial NCT03870490?
This trial is sponsored by Venatorx Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.